Aviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal Year End 2016 Financial Results Conference Call...
September 06 2016 - 5:34PM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing
the next generation of antivirals, announced today that it is
delaying the time of its fourth quarter and fiscal year end 2016
earnings conference call and webcast while it concludes discussions
involving the accounting treatment for its recent sale of its
Inavir® royalty rights to HealthCare Royalty Partners. Aviragen
will announce the new time for its conference call and webcast in
the next several days.
About Aviragen Therapeutics, Inc.Aviragen
Therapeutics is focused on the discovery and development of
the next generation of direct-acting antivirals to treat infections
that have limited therapeutic options and affect a significant
number of patients globally. The Company has three product
candidates in active clinical development: vapendavir, an oral
treatment for human rhinovirus upper (HRV) respiratory infections
in moderate-to-severe asthmatics currently being evaluated in the
Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor
that has received Fast Track designation by the U.S. FDA,
in Phase 2 development for the treatment and prevention of
respiratory syncytial virus (RSV) infections; and BTA074, a topical
antiviral treatment in Phase 2 development for condyloma caused by
human papillomavirus types 6 & 11. For additional information
about the Company, please
visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024